CAR-T Archives

News and Trends 14 Mar 2023

How the microbiome can predict cancer immunotherapy success

A new study shows antibiotic treatment prior to CAR-T cell therapy is connected to unfavorable treatment outcomes. An international team headed by Eran Elinav of the Cancer & Microbiome Division of the German Cancer Research Center (DKFZ), and led by Christoph Stein-Thoeringer, professor of Clinical Infectiology and Translational Microbiome Research at the Medical Faculty of […]

March 14, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Feb 2023

Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer

Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer. The clinical trial to be conducted by Peter Mac will be the first time a CAR-T cell therapy product […]

February 28, 2023 - 4 minutesmins - By Jim Cornall

CAR-T cell therapy, cancer therapy, cell therapy

Interview 17 Feb 2023

The benefits – and challenges – of in-house CAR T-cell therapy

The Sheba Medical Center in Israel has an advanced hemato-oncology center that offers in-house CAR T-cell therapy, the revolutionary immunotherapy that alters a patient’s white blood cells to kill cancer cells. By keeping the entire process at the hospital, and not sending the cells to an external lab, the quality of the T-cells are better […]

February 17, 2023 - 5 minutesmins - By Jim Cornall

Streamlining CAR-T cell therapy manufacturing: a platform approach

Chimeric antigen receptor-T cell (CAR-T) therapy is an exciting treatment modality for blood cancers that do not respond to standard treatment. But manufacturing these CAR-T therapies brings challenges. How can life science companies overcome them to minimize costs and improve patient access? In patients with cancer for whom chemotherapy proves unsuccessful, CAR-T therapy may provide […]

February 7, 2023 - 7 minutesmins - By Alexander Burik

News and Trends 17 Jan 2023

Poolbeg expands POLB 001 into oncology

Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is a strain agnostic, small molecule immunomodulator being studied to address the unmet medical need for a treatment for severe influenza. While investigating the role of cytokine release syndrome (CRS) in severe influenza, Poolbeg discovered data specific to the overt immune […]

January 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

Cartherics granted first patent in China

Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, has been granted a Chinese patent, “Genetically modified cells and uses thereof.” The patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, it covers Cartherics’ chimeric antigen receptor (CAR) targeting tumor-associated glycoprotein-72 (TAG-72), along with T […]

January 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

New biomarker for early prediction of response to CAR-T cell therapy

A MedUni Vienna research team in Austria has discovered a new highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The current findings are an essential step forward towards optimizing this promising therapy. The results of the study were recently published […]

January 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

First CAR-T technology trial for patients with T-cell leukemia subtype authorized

The Spanish Agency of Medicines and Medical Products (AEMPS) has approved the CARxALL clinical trial led by the company OneChain Immunotherapeutics (OCI). It will be the world’s first trial with CAR-T technology for patients with a subtype of T-cell leukemia. The CARxALL trial will evaluate, for the first time, the CAR-T CD1a (OC-1) therapy. This […]

December 22, 2022 - 4 minutesmins - By Jim Cornall

In Depth 20 Dec 2022

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics’ Ebvallo marks the first immunotherapy based on T cells sourced from healthy donors. Since the approvals of Kymriah and Yescarta in 2017, CAR-T immunotherapies have changed the way we treat rare forms of blood cancer. In […]

December 20, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 21 Nov 2022

Legend Biotech small cell lung cancer drug gets FDA ok for clinical development

Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s investigational new drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adult patients with extensive stage small cell lung cancer (SCLC). LB2102 is […]

November 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

SOTIO reveal potential treatment for adults with solid tumors at SITC meeting

SOTIO Biotech has presented preclinical results of its BOXR T cell therapy platform and revealed it indicates a strong clinical path for its first transgene-expressing CAR-T cell as a potential treatment for solid tumors in adults with cancer. The results were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th annual meeting taking place […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 8 Nov 2022

Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma

The Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd (Cartherics) have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL). “Patients with advanced stages of cutaneous T-cell lymphomas often have few treatment options left when their disease […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

CAR-T

How the microbiome can predict cancer immunotherapy success

Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer

The benefits – and challenges – of in-house CAR T-cell therapy

Streamlining CAR-T cell therapy manufacturing: a platform approach

Poolbeg expands POLB 001 into oncology

Cartherics granted first patent in China

New biomarker for early prediction of response to CAR-T cell therapy

First CAR-T technology trial for patients with T-cell leukemia subtype authorized

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Legend Biotech small cell lung cancer drug gets FDA ok for clinical development

SOTIO reveal potential treatment for adults with solid tumors at SITC meeting

Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!